• Fosun Pharma-controlled Fosun Pharmaceutical Industry signed exclusive option agreement with South Korea-based AriBio on May 13 for AR1001, oral PDE-5 inhibitor in Phase III POLARIS-AD trial for early Alzheimer’s disease.
• Option allows Fosun Pharmaceutical Industry to decide within 90 days of receiving topline Phase III data whether to take exclusive rights to develop, register, manufacture, and commercialize AR1001 across global markets excluding China, Hong Kong, Macau, 10 Southeast Asian countries, and certain other territories.
• Agreement sets USD 60 million option fee, payable shortly after signing.
• Exercise would trigger up to USD 180 million in upfront and regulatory milestone payments, including USD 80 million upfront, with additional sales milestones once annual net sales first reach USD 2.5 billion.
• Post-launch economics include low double-digit royalty on annual net sales, paid for 15 years per country from first commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260513-12157918), on May 13, 2026, and is solely responsible for the information contained therein.